SHINPOONG PHARMACEUTICAL CO.,LTD
Financials
Valuation Metrics
SHINPOONG PHARMACEUTICAL CO.,LTD's Market Cap is ₩5211B. At end of 2025 it was ₩7827B. Ranked #455 of 2,421 in KR market (top 19%), #295 of 781 on KOSPI (top 38%), #49 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 21%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 521.10B KRW | KR#455/2,421 Sec#49/231 |
| Revenue | 239.07B KRW | KR#941/2,421 Sec#53/231 |
| Net Income | -746.5M KRW | KR—/2,421 Sec—/231 |
| Total Assets | 366.50B KRW | KR#922/2,421 Sec#58/231 |
| Net Assets | 278.04B KRW | KR#753/2,421 Sec#49/231 |
| Employees | 832 | KR#299/2,421 Sec#24/231 |
| Value | ||
| P/B | 1.87x | KR#1,903/2,421 Sec#142/231 |
| P/S | 2.18x | KR#1,860/2,421 Sec#106/231 |
| EV/EBITDA | 195.21x | KR#1,532/2,421 Sec#105/231 |
| FCF Yield | 2.64% | KR#1,014/2,421 Sec#63/231 |
| Profitability | ||
| ROE | -0.27% | KR#1,563/2,421 Sec#108/231 |
| ROA | -0.20% | KR#1,573/2,421 Sec#108/231 |
| Op. Margin | 1.13% | KR#1,492/2,421 Sec#104/231 |
| Revenue Growth | 6.21% | KR#1,122/2,421 Sec#109/231 |
| Financial Health | ||
| Debt Ratio | 31.82% | KR#624/2,421 Sec#73/231 |
| Total Debt | 52.40B KRW | KR#987/2,421 Sec#67/231 |
| FCF | 13.78B KRW | KR#623/2,421 Sec#34/231 |
| Cash | 48.09B KRW | KR#754/2,421 Sec#45/231 |
| Current Ratio | 2.86x | KR#595/2,421 Sec#78/231 |
| Net Debt/EBITDA | 1.60x | KR#799/2,421 Sec#55/231 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -28.42% | KR#1,515/2,421 Sec#116/231 |
| 1M Return | 14.74% | KR#344/2,421 Sec#19/231 |
| From 52W High | -40.75% | KR#957/2,421 Sec#67/231 |
| 1Y MDD | -54.05% | KR#1,173/2,421 Sec#98/231 |
| Trading | ||
| Volume | 150,404 shares | KR#592/2,421 Sec#45/231 |
| Trading Value | 1.41B KRW | KR#638/2,421 Sec#65/231 |
| Foreign Own. | 4.35% | KR#974/2,421 Sec#87/231 |
| Per Share | ||
| EPS | -13 KRW | KR—/2,421 Sec—/231 |
| BPS | 5,026 KRW | KR#1,487/2,421 Sec#105/231 |
Company Info
Established in 1962 and listed on the Korea Exchange in 1990, the company is a mid-sized pharmaceutical enterprise primarily focusing on the manufacturing and sale of finished pharmaceutical products and active pharmaceutical ingredients. It operates six subsidiaries for overseas market entry in countries like Vietnam, Philippines, Myanmar, and the United States. The company concentrates its mid-to-long-term capabilities on global new drug development and secures domestic market competitiveness by launching improved new drugs and first generics, and fostering highly profitable items into mega-products.